Review of the cardiac long-term effects of therapy for Hodgkin lymphoma

British Journal of Haematology

Volumn 154, Issue 1, 2011, Pages 23-31

  Ng, Andrea K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiology; Hodgkin lymphoma; Radiotherapy

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; MITOXANTRONE; VINBLASTINE; VINCRISTINE;

ANGIOCARDIOGRAPHY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; ECHOCARDIOGRAPHY; FOLLOW UP; HEART INFARCTION; HODGKIN DISEASE; HUMAN; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HODGKIN DISEASE; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; RADIATION INJURIES; RADIOTHERAPY;

EID: 79958841702     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08713.x     Document Type: Review

References (64)

1. Adams, M.J., Lipsitz, S.R., Colan, S.D., Tarbell, N.J., Treves, S.T., Diller, L., Greenbaum, N., Mauch, P. & Lipshultz, S.E. (2004) Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. Journal of Clinical Oncology, 22, 3139-3148.
2. Aleman, B.M., van den Belt-Dusebout, A.W., Klokman, W.J., Van't Veer, M.B., Bartelink, H. & van Leeuwen, F.E. (2003) Long-term cause-specific mortality of patients treated for Hodgkin's disease. Journal of Clinical Oncology, 21, 3431-3439.
3. Aleman, B.M., van den Belt-Dusebout, A.W., De Bruin, M.L., van 't Veer, M.B., Baaijens, M.H., de Boer, J.P., Hart, A.A., Klokman, W.J., Kuenen, M.A., Ouwens, G.M., Bartelink, H. & van Leeuwen, F.E. (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood, 109, 1878-1886.
4. Aviles, A., Neri, N., Nambo, J.M., Huerta-Guzman, J., Talavera, A. & Cleto, S. (2005) Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leukaemia & Lymphoma, 46, 1023-1028.
5. Balady, G.J., Larson, M.G., Vasan, R.S., Leip, E.P., O'Donnell, C.J. & Levy, D. (2004) Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. Circulation, 110, 1920-1925.
6. Berman, D.S., Shaw, L.J., Hachamovitch, R., Friedman, J.D., Polk, D.M., Hayes, S.W., Thomson, L.E., Germano, G., Wong, N.D., Kang, X. & Rozanski, A. (2007) Comparative use of radionuclide stress testing, coronary artery calcium scanning, and noninvasive coronary angiography for diagnostic and prognostic cardiac assessment. Seminars in Nuclear Medicine, 37, 2-16.
7. Boivin, J.F., Hutchison, G.B., Lubin, J.H. & Mauch, P. (1992) Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer, 69, 1241-1247.
8. Bonadonna, G., Bonfante, V., Viviani, S., Di Russo, A., Villani, F. & Valagussa, P. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. Journal of Clinical Oncology, 22, 2835-2841.
9. Bovelli, D., Plataniotis, G. & Roila, F. (2010) Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology, 21(Suppl. 5), v277-v282.
10. Castellino, S.M., Geiger, A.M., Mertens, A.C., Leisenring, W.M., Tooze, J.A., Goodman, P., Stovall, M., Robison, L.L. & Hudson, M.M. (2011) Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood, 117, 1806-1816.
11. Cella, L., Liuzzi, R., Magliulo, M., Conson, M., Camera, L., Salvatore, M. & Pacelli, R. (2011) Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques. Radiation Oncology, 5, 33.
12. Children's Oncology Group. (2008) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 3.0. Available at.
13. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dorken, B., Muller-Hermelink, H.K., Duhmke, E. & Loeffler, M. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386-2395.
14. Eich, H.T., Muller, R.P., Engenhart-Cabillic, R., Lukas, P., Schmidberger, H., Staar, S. & Willich, N. (2008) Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlentherapie und Onkologie, 184, 406-410.
15. Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., De Wit, M., Mezger, J., Duhmke, E., Willich, N., Muller, R.P., Schmidt, B.F., Renner, H., Muller-Hermelink, H.K., Pfistner, B., Wolf, J., Hasenclever, D., Loffler, M. & Diehl, V. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology, 21, 3601-3608.
16. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W.D., Koch, P., Hanel, M., Pfreundschuh, M., Wilhelm, M., Trumper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Muller-Hermelink, H.K., Hasenclever, D. & Loffler, M. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology, 27, 4548-4554.
17. Engert, A., Plutschow, A., Eich, H.T., Lohri, A., Dorken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K.C., Wilhelm, M., Debus, J., Eble, M.J., Sokler, M., Ho, A., Rank, A., Ganser, A., Trumper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Kral, Z., Fuchs, M., Muller-Hermelink, H.K., Muller, R.P. & Diehl, V. (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. New England Journal of Medicine, 363, 640-652.
18. Eriksson, F., Gagliardi, G., Liedberg, A., Lax, I., Lee, C., Levitt, S., Lind, B. & Rutqvist, L.E. (2000) Long-term cardiac mortality following radiation therapy for Hodgkin's disease: analysis with the relative seriality model. Radiotherapy and Oncology, 55, 153-162.
19. Faglia, E., Manuela, M., Antonella, Q., Michela, G., Vincenzo, C., Maurizio, C., Roberto, M. & Alberto, M. (2005) Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. American Heart Journal, 149, e1-e6.
20. Federico, M., Luminari, S., Iannitto, E., Polimeno, G., Marcheselli, L., Montanini, A., La Sala, A., Merli, F., Stelitano, C., Pozzi, S., Scalone, R., Di Renzo, N., Musto, P., Baldini, L., Cervetti, G., Angrilli, F., Mazza, P., Brugiatelli, M. & Gobbi, P.G. (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology, 27, 805-811.
21. Ferme, C., Eghbali, H., Meerwaldt, J.H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M.B., Walewski, J.A., Lederlin, P., Tirelli, U., Carde, P., Van den Neste, E., Gyan, E., Monconduit, M., Divine, M., Raemaekers, J.M., Salles, G., Noordijk, E.M., Creemers, G.J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vie, B., Kluin-Nelemans, J.C., Viseu, F., Baars, J.W., Poortmans, P., Lugtenburg, P.J., Carrie, C., Jaubert, J. & Henry-Amar, M. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New England Journal of Medicine, 357, 1916-1927.
22. Galper, S.L., Yu, J.B., Mauch, P.M., Strasser, J.F., Silver, B., Lacasce, A., Marcus, K.J., Stevenson, M.A., Chen, M.H. & Ng, A.K. (2011) Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood, 117, 412-418.
23. Ghalibafian, M., Beaudre, A. & Girinsky, T. (2008) Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: dose constraints to virtual volumes or to organs at risk? Radiotherapy and Oncology, 87, 82-88.
24. Girinsky, T. & Ghalibafian, M. (2005) Radiation treatment in non Hodgkin's lymphomas: present and future directions. Cancer Radiotherapy, 9, 422-426.
25. Girinsky, T., van der Maazen, R., Specht, L., Aleman, B., Poortmans, P., Lievens, Y., Meijnders, P., Ghalibafian, M., Meerwaldt, J. & Noordijk, E. (2006a) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiotherapy and Oncology, 79, 270-277.
26. Girinsky, T., Pichenot, C., Beaudre, A., Ghalibafian, M. & Lefkopoulos, D. (2006b) Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? International Journal of Radiation Oncology, Biology, Physics, 64, 218-226.
27. Glanzmann, C., Kaufmann, P., Jenni, R., Hess, O.M. & Huguenin, P. (1998) Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiotherapy and Oncology, 46, 51-62.
28. Goff, Jr, D.C., Bertoni, A.G., Kramer, H., Bonds, D., Blumenthal, R.S., Tsai, M.Y. & Psaty, B.M. (2006) Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation, 113, 647-656.
29. Gordon, L., Hong, F., Fisher, R., Bartlett, N., Connors, J., Gascoyne, R., Wagner, H., Stiff, P., Cheson, B., Gospodarowicz, M., Advani, R., Kahl, B., Friedberg, J., Blum, K., Habermann, T., Tuscano, J., Hoppe, R. & Horning, S. (2010) A randomized phase III trial of ABVD Vs. Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496). Blood (ASH Annual Meeting Abstracts), 116, 415.
30. Hancock, S.L., Tucker, M.A. & Hoppe, R.T. (1993a) Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA, 270, 1949-1955.
31. Hancock, S.L., Donaldson, S.S. & Hoppe, R.T. (1993b) Cardiac disease following treatment of Hodgkin's disease in children and adolescents. Journal of Clinical Oncology, 11, 1208-1215.
32. Heidenreich, P.A., Hancock, S.L., Lee, B.K., Mariscal, C.S. & Schnittger, I. (2003) Asymptomatic cardiac disease following mediastinal irradiation. Journal of the American College of Cardiology, 42, 743-749.
33. Heidenreich, P.A., Schnittger, I., Hancock, S.L. & Atwood, J.E. (2004) A systolic murmur is a common presentation of aortic regurgitation detected by echocardiography. Clinical Cardiology, 27, 502-506.
34. Heidenreich, P.A., Hancock, S.L., Vagelos, R.H., Lee, B.K. & Schnittger, I. (2005) Diastolic dysfunction after mediastinal irradiation. American Heart Journal, 150, 977-982.
35. Heidenreich, P.A., Schnittger, I., Strauss, H.W., Vagelos, R.H., Lee, B.K., Mariscal, C.S., Tate, D.J., Horning, S.J., Hoppe, R.T. & Hancock, S.L. (2007) Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. Journal of Clinical Oncology, 25, 43-49.
36. Henry-Amar, M., Hayat, M., Meerwaldt, J.H., Burgers, M., Carde, P., Somers, R., Noordijk, E.M., Monconduit, M., Thomas, J. & Cosset, J.M. (1990) Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. International Journal of Radiation Oncology, Biology, Physics, 19, 1155-1157.
37. Hoppe, R.T. (1997) Hodgkin's disease: complications of therapy and excess mortality. Annals of Oncology, 8(Suppl. 1), 115-118.
38. Hoskin, P.J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B.W., Smith, P., Qian, W., Patrick, P., Popova, B., Pettitt, A., Cunningham, D., Pettengell, R., Sweetenham, J., Linch, D. & Johnson, P.W. (2009) Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 27, 5390-5396.
39. Hull, M.C., Morris, C.G., Pepine, C.J. & Mendenhall, N.P. (2003) Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA, 290, 2831-2837.
40. Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W.H., Zijlstra, J.M., Bockisch, A., Weckesser, M., Lorenz, R., Schreckenberger, M., Bares, R., Eich, H.T., Mueller, R.P., Fuchs, M., Borchmann, P., Schicha, H., Diehl, V. & Engert, A. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood, 112, 3989-3994.
41. Kupeli, S., Hazirolan, T., Varan, A., Akata, D., Alehan, D., Hayran, M., Besim, A. & Buyukpamukcu, M. (2010) Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma. Journal of Clinical Oncology, 28, 1025-1030.
42. Lipshultz, S.E., Scully, R.E., Lipsitz, S.R., Sallan, S.E., Silverman, L.B., Miller, T.L., Barry, E.V., Asselin, B.L., Athale, U., Clavell, L.A., Larsen, E., Moghrabi, A., Samson, Y., Michon, B., Schorin, M.A., Cohen, H.J., Neuberg, D.S., Orav, E.J. & Colan, S.D. (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncology, 11, 950-961.
43. Mladosievicova, B., Foltinova, A., Petrasova, H., Bernadic, M. & Hulin, I. (2001) Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane. Neoplasma, 48, 61-65.
44. Mora, S., Redberg, R.F., Cui, Y., Whiteman, M.K., Flaws, J.A., Sharrett, A.R. & Blumenthal, R.S. (2003) Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA, 290, 1600-1607.
45. Mora, S., Redberg, R.F., Sharrett, A.R. & Blumenthal, R.S. (2005) Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation, 112, 1566-1572.
46. Myrehaug, S., Pintilie, M., Tsang, R., Mackenzie, R., Crump, M., Chen, Z., Sun, A. & Hodgson, D.C. (2008) Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leukaemia & Lymphoma, 49, 1486-1493.
47. Myrehaug, S., Pintilie, M., Yun, L., Crump, M., Tsang, R.W., Meyer, R.M., Sussman, J., Yu, E. & Hodgson, D.C. (2010) A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood, 116, 2237-2240.
48. Nasir, K., Michos, E.D., Blumenthal, R.S. & Raggi, P. (2005) Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III Guidelines. Journal of the American College of Cardiology, 46, 1931-1936.
49. National Comprehensive Cancer Network. (2010) NCCN Clinical Practice Guidelines in Oncology, v.2.2010. Available at.
50. Ng, A.K., Bernardo, M.P., Weller, E., Backstrand, K.H., Silver, B., Marcus, K.C., Tarbell, N.J., Friedberg, J., Canellos, G.P. & Mauch, P.M. (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. Journal of Clinical Oncology, 20, 2101-2108.
51. Ng, A., Constine, L.S., Advani, R., Das, P., Flowers, C., Friedberg, J., Hodgson, D.C., Schwartz, C.L., Wilder, R.B., Wilson, L.D. & Yunes, M.J. (2010) ACR appropriateness criteria: follow-up of Hodgkin's lymphoma. Current Problems in Cancer, 34, 211-227.
52. Pilote, L., Pashkow, F., Thomas, J.D., Snader, C.E., Harvey, S.A., Marwick, T.H. & Lauer, M.S. (1998) Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. American Journal of Cardiology, 81, 219-224.
53. Pletcher, M.J., Tice, J.A., Pignone, M. & Browner, W.S. (2004) Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Archives of Internal Medicine, 164, 1285-1292.
54. Rademaker, J., Schoder, H., Ariaratnam, N.S., Strauss, H.W., Yahalom, J., Steingart, R. & Oeffinger, K.C. (2008) Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR. American Journal of Roentgenology, 191, 32-37.
55. Raggi, P. & Berman, D.S. (2005) Computed tomography coronary calcium screening and myocardial perfusion imaging. Journal of Nuclear Cardiology, 12, 96-103.
56. van Rijswijk, R.E., Verbeek, J., Haanen, C., Dekker, A.W., van Daal, W.A. & van Peperzeel, H.A. (1987) Major complications and causes of death in patients treated for Hodgkin's disease. Journal of Clinical Oncology, 5, 1624-1633.
57. Singh, J.P., Evans, J.C., Levy, D., Larson, M.G., Freed, L.A., Fuller, D.L., Lehman, B. & Benjamin, E.J. (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). American Journal of Cardiology, 83, 897-902.
58. Siscovick, D.S., Ekelund, L.G., Johnson, J.L., Truong, Y. & Adler, A. (1991) Sensitivity of exercise electrocardiography for acute cardiac events during moderate and strenuous physical activity. The lipid research clinics coronary primary prevention trial. Archives of Internal Medicine, 151, 325-330.
59. Smith, L.A., Cornelius, V.R., Plummer, C.J., Levitt, G., Verrill, M., Canney, P. & Jones, A. (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 337.
60. Sorajja, P., Chareonthaitawee, P., Rajagopalan, N., Miller, T.D., Frye, R.L., Hodge, D.O. & Gibbons, R.J. (2005) Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation, 112, I311-I316.
61. Swerdlow, A.J., Higgins, C.D., Smith, P., Cunningham, D., Hancock, B.W., Horwich, A., Hoskin, P.J., Lister, A., Radford, J.A., Rohatiner, A.Z. & Linch, D.C. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. Journal of the National Cancer Institute, 99, 206-214.
62. Tebbi, C.K., London, W.B., Friedman, D., Villaluna, D., De Alarcon, P.A., Constine, L.S., Mendenhall, N.P., Sposto, R., Chauvenet, A. & Schwartz, C.L. (2007) Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. Journal of Clinical Oncology, 25, 493-500.
63. Testore, F., Milanese, S., Ceste, M., de Conciliis, E., Parello, G., Lanfranco, C., Manfredi, R., Ferrero, G., Simoni, C., Miglietta, L., Ferro, S., Giaretto, L. & Bosso, G. (2008) Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. American Journal of Cardiovascular Drugs, 8, 257-263.
64. Young, L.H., Wackers, F.J., Chyun, D.A., Davey, J.A., Barrett, E.J., Taillefer, R., Heller, G.V., Iskandrian, A.E., Wittlin, S.D., Filipchuk, N., Ratner, R.E. & Inzucchi, S.E. (2009) Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA, 301, 1547-1555.